Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.78
+0.15009.20%
Post-market: 1.920.1400+7.87%19:30 EDT
Volume:275.01K
Turnover:493.29K
Market Cap:87.48M
PE:-8.14
High:1.84
Open:1.67
Low:1.67
Close:1.63
52wk High:3.90
52wk Low:1.17
Shares:49.15M
Float Shares:43.50M
Volume Ratio:0.44
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2188
EPS(LYR):-0.2445
ROE:-25.56%
ROA:-16.41%
PB:2.35
PE(LYR):-7.28

Loading ...

MediciNova initiated with a Buy at Roth Capital

TIPRANKS
·
Sep 17

MediciNova Joins H.C. Wainwright Global Investment Conference in September

Reuters
·
Sep 08

MediciNova to Participate in Two Investor Conferences in September

GlobeNewswire
·
Sep 08

MediciNova Ends Standby Equity Financing Agreement

TIPRANKS
·
Sep 02

Medicinova - no Fees Due by Medicinova or Yorkville for Termination of Sepa - SEC Filing

THOMSON REUTERS
·
Sep 02

Medicinova - Delivers Notice to Terminate Standby Equity Purchase Agreement on Aug 31, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

3 Promising Penny Stocks With Over $50M Market Cap

Simply Wall St.
·
Aug 26

MediciNova CEO Iwaki Base Salary Rises to $690,246 Under New Employment Agreement

Reuters
·
Aug 19

Jason McCarthy Reiterates Buy on MediciNova, Maintains $6 Price Target Ahead of Key ALS and Metabolic Disease Readouts

TIPRANKS
·
Aug 15

MediciNova Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

MediciNova Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 08

MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

TIPRANKS
·
Jul 16

Medicinova Announces Patient Enrollment Milestone Achieved in Seanobi Study Expanded-access-program Evaluating Mn‑166 (ibudilast) in ALS Patients

THOMSON REUTERS
·
Jul 15

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

GlobeNewswire
·
Jul 15

Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target

TIPRANKS
·
Jul 02

Medicinova Says US Patent Office Allows Ibudilast–anti-pd-1 Combo Claims for Glioblastoma Treatment

Reuters
·
Jun 30

Medicinova CEO Provides Shareholder Update

THOMSON REUTERS
·
Jun 30

MediciNova CEO Provides Shareholder Update

GlobeNewswire
·
Jun 30

Medicinova Stockholders Reject Proposal to Boost Authorized Common Shares to 247 Million

Reuters
·
Jun 25